Inclusion Criteria:

- 18 years of age or older

- Advanced or metastatic solid tumor malignancy

- ECOG performance status of less than or equal to 1

- Life expectancy of greater than 3 months

- At least 4 weeks must have elapsed between prior investigational therapy,
chemotherapy, or radiotherapy, and the first dose of deforolimus

- Adequate hematological, hepatic and renal function

- Serum cholesterol less than or equal to 350 mg/dL and triglycerides less than or
equal to 400 mg/dL

- Signed informed consent

- Women of childbearing potential must have a negative serum pregnancy test within 7
days of starting therapy and must use an approved contraceptive method from time of
screening until 30 days after the last dose of study drug

Exclusion Criteria:

- Tumor location in close proximity to a major blood vessel

- History of brain metastases, spinal cord compression, or carcinomatous meningitis.
Primary brain tumors (for example, glioblastoma) are allowed.

- New brain metastases, spinal cord compression, or leptomeningeal metastases on
screening CT scan or MRI

- Hemoptysis or hematemesis within 28 days prior to entering the trial

- Clinical significant unexplained bleeding within 28 days prior to entering the trial

- Uncontrolled hypertension

- Proteinuria at screening

- Clinically significant cardiovascular disease

- Newly diagnosed or poorly controlled type 1 or 2 diabetes

- Active infection requiring prescribed intervention

- Other concurrent illness that, in the Investigator's judgement, would either
compromise the patient's safety or interfere with the evaluation of the safety of the
study drug

- Major surgery within 28 days before trial entry, or any incompletely healed surgical
incision; minor surgery or procedures within 7 days

- Pregnant or breastfeeding

- Known allergy to macrolide antibiotics

- Known hypersensitivity to any component of bevacizumab

- Concurrent treatment with medications that strongly induce or inhibit cytochrome P450
(CYP3A)

- Known history of HIV sero-positivity

- Any condition in the Investigator's judgement that renders the patient unable to
fully understand and provide informed consent and/or comply with the protocol